Intec Pharma Ltd (NASDAQ:NTEC)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a research report issued on Friday. They presently have a $9.00 target price on the stock. Maxim Group’s price objective indicates a potential upside of 78.22% from the stock’s current price.
Shares of Intec Pharma (NASDAQ:NTEC) traded down 0.98% during midday trading on Friday, hitting $5.05. 620 shares of the company were exchanged. Intec Pharma has a one year low of $3.03 and a one year high of $6.36. The firm’s 50 day moving average price is $4.83 and its 200 day moving average price is $5.22. The firm’s market capitalization is $57.56 million.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.mideasttime.com/maxim-group-reiterates-buy-rating-for-intec-pharma-ltd-ntec/1587281.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.